KRAS and cancer: Together, these results indicate that genome editing with SpCas9D10A nickases might offer a heightened safety profile to engineered cell products derived from iPSCs in that, besides cell-cycle arrest and apoptosis, DSB-induced signalling pathways have been linked to the selection of cells with mutations in cancer-associated genes, i.e. TP53 and KRAS (31,32).